Experienced family doctor Ray Strand writes his patients prescriptions every week, but he also believes that prescribing drugs should be a last resort in most medical cases-not a first choice. In Death by Prescription he provides simple guidelines to help readers protect themselves and their families from suffering adverse reactions to prescription medication.
Fifteen-year-old Vanessa Young began taking Prepulsid after her doctor prescribed the billion-dollar selling drug to alleviate a stomach disorder. Neither she--nor her parents--had any reason to suspect the drug might pose a risk. The doctor had prescribed the drug without concern. Nothing in the literature from the manufacturer warned of complications. On March 19, 2000, Vanessa died. Shattered by grief and angry beyond belief, Terence Young began a long fight to find out why. The answer: Prepulsid. The prescription drug the teenager had been assured would relieve her symptoms had, in fact, killed her. Not content to know why, Young determined to battle the industry to make sure this kind of tragedy never happened again. Then a successful businessman and former member of Parliament, Young pursued answers with a kind of Quixote-like obsession. The truth is, as he would find out, that every year hundreds and hundreds of people die as a result of complications from prescription drugs. And most of these companies attentive only to their own bottom line simply don't care. Death by Prescription is the unforgettable story of his fight to find justice for his daughter and a shocking wake-up call to the millions of patients out there who are potential victims of the greedy pharmaceutical companies that put profits ahead of patients.
When her comatose husband died in the ICU while on life support, the whispers about Dr. Allison Williams began. Another death during her training puts her under suspicion. When the pattern is repeated in the hospital where she is attempting to start over, the whispers turn into a shout: “mercy killing.” What is the dark secret that keeps Allison’s lips sealed when she should be defending herself? Despite her move to a new city, the midnight phone calls that started after her husband’s death follow Allison. Who is the woman who sobs out, “I know what you did?” What does she mean by “You’ll pay?” And what can Allison do to prevent it? Two physicians, widowers themselves, offer support, telling Allison they know what she is going through after the death of her husband. But do they? And is it safe to trust either of them with her secret?
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
This hard-hitting expose does for prescription drugs what "Silent Spring" did for pesticides, revealing the hidden dangers of the most commonly prescribed medications--and what the consumer can do to minimize the risks of serious side effects.
The recent deaths of celebrities like Michael Jackson, Anna Nicole Smith, Heath Ledger, and Whitney Houston have shown a spotlight on the overuse and abuse of prescription drugs. Most people believe that prescription drugs are safer than illegal substances. But, when combined with other over-the-counter sedatives, prescription drugs can be every bit as powerful, addictive, and dangerous. In 2006, overdoses on a class of prescription pain relievers called opioid analgesics killed more people than those killed by overdoses on cocaine and heroin combined. Right now, among 35 to 54 year olds, poisoning by prescription drugs is the most common cause of accidental death—even more so than auto-related deaths. In Medicines That Kill, Dr. Marcum shines a light on the addictive power of prescription medication and how you can protect yourself and your family by practicing healthy habits.
A New York Times Critics’ Top Ten Book of the Year * 2021 Edgar Award Winner Best Fact Crime * A Lit Hub Best Book of The Year From a Pulitzer Prize–winning investigative reporter at the Charleston Gazette-Mail, a “powerful,” (The New York Times) urgent, and heartbreaking account of the corporate greed that pumped millions of pain pills into small Appalachian towns, decimating communities. In a pharmacy in Kermit, West Virginia, 12 million opioid pain pills were distributed in just three years to a town with a population of 382 people. One woman, after losing her brother to overdose, was desperate for justice. Debbie Preece’s fight for accountability for her brother’s death took her well beyond the Sav-Rite Pharmacy in coal country, ultimately leading to three of the biggest drug wholesalers in the country. She was joined by a crusading lawyer and by local journalist, Eric Eyre, who uncovered a massive opioid pill-dumping scandal that shook the foundation of America’s largest drug companies—and won him a Pulitzer Prize. Part Erin Brockovich, part Spotlight, Death in Mud Lick details the clandestine meetings with whistleblowers; a court fight to unseal filings that the drug distributors tried to keep hidden, a push to secure the DEA pill-shipment data, and the fallout after Eyre’s local paper, the Gazette-Mail, the smallest newspaper ever to win a Pulitzer Prize for investigative reporting, broke the story. Eyre follows the opioid shipments into individual counties, pharmacies, and homes in West Virginia and explains how thousands of Appalachians got hooked on prescription drugs—resulting in the highest overdose rates in the country. But despite the tragedy, there is also hope as citizens banded together to create positive change—and won. “A product of one reporter’s sustained outrage [and] a searing spotlight on the scope and human cost of corruption and negligence” (The Washington Post) Eric Eyre’s intimate portrayal of a national public health crisis illuminates the shocking pattern of corporate greed and its repercussions for the citizens of West Virginia—and the nation—to this day.
The major pharmaceutical companies, according to John le Carré – who has based his novel The Constant Gardener on their depredations – “are engaged in the systematic corruption of the medical profession, country by country.” Jeffrey Robinson can back up that charge. In Prescription Games, Jeffrey Robinson exposes the yawning abyss between the claims to altruism made by pharmaceutical companies and the harsh reality of their everyday practice. When the industry claims that the enormous markup they charge for new drugs pays the cost of developing new ones, they don’t say that as much as 80 per cent of R&D money is actually directed at developing drugs designed to compete with existing brands, or at creating variations on drugs whose patents are about to expire – expenditures only the industry itself (and its shareholders) will benefit from. Within the industry, there are “blockbuster” drugs that create vast wealth for the companies that manufacture them. Most are designed to treat conditions that are endemic among prosperous, western populations that can afford them. But there are no blockbuster drugs to treat diseases like tuberculosis, cholera, and malaria that ravage the Third World, because Third World countries can’t afford the prices. People in Africa and Asia die from new strains of tuberculosis while people in Europe and North America are offered expensive treatments for obesity, hair loss, and sexual dysfunction. In this hard-hitting exposé, Robinson also examines the extension of patent protection, the end of generic drug competition in Canada, the Nancy Olivieri scandal (how a drug manufacturer fought to conceal research findings that would damage sales of its product), the illicit drug trade, and espionage among drug manufacturers.
The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.
